Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6707460 | 0.99 | SIGMAR1 (0.43) | SIGMAR1ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833647 | 0.81 | ROCK2 (0.45) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833283 | 0.81 | GBA1 (0.46) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL6708297 | 0.79 | DRD2 (0.47) | — | |
| SCHEMBL6713113 | 0.79 | PKM (0.40) | ROCK2ARHGDIAROCK1 | |
| SCHEMBL9678342 | 0.78 | SIGMAR1 (0.45) | SIGMAR1ROCK2ARHGDIAROCK1MAPT | |
| Hydrochloric Acid SCHEMBL6709532 | 0.78 | DRD2 (0.46) | — | |
| Hydrochloric Acid SCHEMBL6712863 | 0.78 | PKM (0.40) | ROCK2ARHGDIAROCK1 | |
| SCHEMBL6711337 | 0.78 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL5833935 | 0.78 | ROCK2 (0.41) | SIGMAR1ROCK2ARHGDIAROCK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | claimed |
| EP-1379502-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | claimed |
| WO-2002083640-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | claimed |
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| EP-1379502-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002083640-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | CHRNA1, CHRNA2, CHRNA10 | SIGMAR1 390/4885ROCK2 2334/4885ARHGDIA 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.